Seung Y. Chu

1.8k total citations
40 papers, 1.4k citations indexed

About

Seung Y. Chu is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, Seung Y. Chu has authored 40 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Radiology, Nuclear Medicine and Imaging, 26 papers in Immunology and 11 papers in Molecular Biology. Recurrent topics in Seung Y. Chu's work include Monoclonal and Polyclonal Antibodies Research (37 papers), T-cell and B-cell Immunology (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Seung Y. Chu is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (37 papers), T-cell and B-cell Immunology (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Seung Y. Chu collaborates with scholars based in United States, Germany and South Korea. Seung Y. Chu's co-authors include John R. Desjarlais, Erik Pong, Sher Karki, David E. Szymkowski, Eugene A. Zhukovsky, Greg A. Lazar, Gregory L. Moore, Matthew J. Bernett, Holly M. Horton and Irene Leung and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Seung Y. Chu

39 papers receiving 1.3k citations

Peers

Countries citing papers authored by Seung Y. Chu

Since Specialization

Citations

This map shows the geographic impact of Seung Y. Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seung Y. Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seung Y. Chu more than expected).

Fields of papers citing papers by Seung Y. Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seung Y. Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seung Y. Chu. The network helps show where Seung Y. Chu may publish in the future.

Co-authorship network of co-authors of Seung Y. Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Seung Y. Chu. A scholar is included among the top collaborators of Seung Y. Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seung Y. Chu. Seung Y. Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1372 XmAb143, an engineered IL18 heterodimeric Fc-fusion, features improved stability, reduced potency, and insensitivity to IL18BP 2022 ·Regular and Young Investigator Award Abstracts ·Alex Nisthal, Sung‐Hyung Lee, Christine Bonzon, Ruschelle Love, Kendra N. Avery, Rumana Rashid, Panida Lertkiatmongkol, (unknown), Sher Karki, Norman J. Barlow, Seung Y. Chu, Gregory Moore, John R. Desjarlais	3
2	Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcγRIIb on Liver Sinusoidal Endothelial Cells by Endocytosis 2021 ·The Journal of Immunology ·(unknown), (unknown), (unknown), (unknown), (unknown), Menakshi Bhat, Qian Wu, Erik Pong, Seung Y. Chu, David E. Szymkowski, Amit Sharma, Stéphanie Seveau, John M. Robinson, Jesse J. Kwiek, Dennis R. Burton, Murugesan V. S. Rajaram, Jonghan Kim, Lars Hangartner, Latha P. Ganesan	6
3	Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice 2020 ·SHILAP Revista de lepidopterología ·Seung Y. Chu, Erik Pong, Christine Bonzon, Ning Yu, Chaim O. Jacob, Samantha A. Chalmers, Chaim Putterman, David E. Szymkowski, William Stohl	17
4	Abstract 5663: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models 2020 ·Cancer Research ·Alex Nisthal, Matthew A. Dragovich, Erik Pong, (unknown), Michael Hedvat, Christine Bonzon, Kendra N. Avery, Rumana Rashid, (unknown), Umesh S. Muchhal, Gregory L. Moore, Seung Y. Chu, John R. Desjarlais	1
5	Abstract 2784: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation 2018 ·Cancer Research ·Michael Hedvat, Christine Bonzon, Matthew J. Bernett, Gregory L. Moore, Kendra N. Avery, Rumana Rashid, Alex Nisthal, (unknown), Rajat Varma, Sung‐Hyung Lee, (unknown), Irene Leung, Seung Y. Chu, Umesh S. Muchhal, John R. Desjarlais	7
6	A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats 2018 ·Methods ·Gregory L. Moore, Matthew J. Bernett, Rumana Rashid, Erik Pong, Duc-Hanh T. Nguyen, Jonathan Jacinto, Araz Eivazi, Alex Nisthal, Juan E. Diaz, Seung Y. Chu, Umesh S. Muchhal, John R. Desjarlais	49
7	Abstract 3633: Anti-SSTR2 × anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors 2017 ·Cancer Research ·Sung‐Hyung Lee, Seung Y. Chu, Rumana Rashid, Sheryl Phung, Irene Leung, Umesh S. Muchhal, Gregory L. Moore, Matthew J. Bernett, Suzanne Schubbert, (unknown), Christine Bonzon, Paul Foster, David E. Szymkowski, John R. Desjarlais	11
8	Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia 2014 ·Blood ·Seung Y. Chu, Erik Pong, Hsing Chen, Sheryl Phung, Emily Chan, (unknown), Rumana Rashid, Christine Bonzon, Irene Leung, Umesh S. Muchhal, Gregory L. Moore, Matthew J. Bernett, David E. Szymkowski, John R. Desjarlais	34
9	Immune suppression in cynomolgus monkeys by XPro9523 2013 ·mAbs ·Matthew J. Bernett, Seung Y. Chu, Irene Leung, Gregory L. Moore, Sung‐Hyung Lee, Erik Pong, Hsing Chen, Sheryl Phung, Umesh S. Muchhal, Holly M. Horton, Greg A. Lazar, John R. Desjarlais, David E. Szymkowski	22
10	Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor 2013 ·Arthritis & Rheumatology ·Seung Y. Chu, (unknown), (unknown), Erik Pong, Yvonne Miranda, Sheryl Phung, Hsing Chen, Sung‐Hyung Lee, Irene Leung, Christine Bonzon, John R. Desjarlais, William Stohl, David E. Szymkowski	51
11	Suppression of mast cell degranulation through a dual-targeting tandem IgE–IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb 2012 ·Immunology Letters ·Sašo Čemerski, Seung Y. Chu, Gregory L. Moore, Umesh S. Muchhal, John R. Desjarlais, David E. Szymkowski	26
12	Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody 2012 ·Journal of Allergy and Clinical Immunology ·Seung Y. Chu, Holly M. Horton, Erik Pong, Irene Leung, Hsing Chen, Duc-Hanh T. Nguyen, (unknown), Umesh S. Muchhal, Matthew J. Bernett, Gregory L. Moore, David E. Szymkowski, John R. Desjarlais	72
13	A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens 2011 ·mAbs ·Gregory L. Moore, (unknown), Erik Pong, Duc-Hanh T. Nguyen, Jonathan Jacinto, Araz Eivazi, Umesh S. Muchhal, Sher Karki, Seung Y. Chu, Greg A. Lazar	89
14	Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia 2008 ·Cancer Research ·Holly M. Horton, Matthew J. Bernett, Erik Pong, Matthias Peipp, Sher Karki, Seung Y. Chu, John O. Richards, Igor Voštiar, Patrick F. Joyce, Roland Repp, John R. Desjarlais, Eugene A. Zhukovsky	187
15	Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies 2008 ·Molecular Immunology ·Seung Y. Chu, Igor Voštiar, Sher Karki, Gregory L. Moore, Greg A. Lazar, Erik Pong, Patrick F. Joyce, David E. Szymkowski, John R. Desjarlais	119
16	An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma 2008 ·Blood ·Eugene A. Zhukovsky, Holly M. Horton, Matthias Peipp, Erik Pong, Matthew J. Bernett, Sher Karki, John O. Richards, Seung Y. Chu, Roland Repp, John R. Desjarlais	1
17	Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective 2007 ·Drug Discovery Today ·John R. Desjarlais, Greg A. Lazar, Eugene A. Zhukovsky, Seung Y. Chu	96
18	Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity 2005 ·Clinical Immunology ·Maria D.F.S. Barbosa, Jost Vielmetter, Seung Y. Chu, David Smith, Jonathan Jacinto	62
19	Crystal Structure of the YchF Protein Reveals Binding Sites for GTP and Nucleic Acid 2003 ·Journal of Bacteriology ·A. Teplyakov, Galina Obmolova, Seung Y. Chu, (unknown), Edward Eisenstein, Andrew Howard, Gary L. Gilliland	49
20	The Structure of the T127L/S128A Mutant of cAMP Receptor Protein Facilitates Promoter Site Binding 2001 ·Journal of Biological Chemistry ·Seung Y. Chu, Mária Tordová, Gary L. Gilliland, Inna Gorshkova, Ying Shi, (unknown), Frederick P. Schwarz	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact